258 related articles for article (PubMed ID: 38155202)
1. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
[TBL] [Abstract][Full Text] [Related]
2. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Møllerhøj MB; Veidal SS; Thrane KT; Oró D; Overgaard A; Salinas CG; Madsen MR; Pfisterer L; Vyberg M; Simon E; Broermann A; Vrang N; Jelsing J; Feigh M; Hansen HH
Clin Transl Sci; 2022 May; 15(5):1167-1186. PubMed ID: 35143711
[TBL] [Abstract][Full Text] [Related]
3. Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Flensted-Jensen M; Oró D; Rørbeck EA; Zhang C; Madsen MR; Madsen AN; Norlin J; Feigh M; Larsen S; Hansen HH
BMC Gastroenterol; 2024 Feb; 24(1):59. PubMed ID: 38308212
[TBL] [Abstract][Full Text] [Related]
4. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
[TBL] [Abstract][Full Text] [Related]
5. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis.
Hansen HH; Ægidius HM; Oró D; Evers SS; Heebøll S; Eriksen PL; Thomsen KL; Bengtsson A; Veidal SS; Feigh M; Suppli MP; Knop FK; Grønbæk H; Miranda D; Trevaskis JL; Vrang N; Jelsing J; Rigbolt KTG
BMC Gastroenterol; 2020 Jul; 20(1):210. PubMed ID: 32631250
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
7. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
[TBL] [Abstract][Full Text] [Related]
9. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.
Boland ML; Oró D; Tølbøl KS; Thrane ST; Nielsen JC; Cohen TS; Tabor DE; Fernandes F; Tovchigrechko A; Veidal SS; Warrener P; Sellman BR; Jelsing J; Feigh M; Vrang N; Trevaskis JL; Hansen HH
World J Gastroenterol; 2019 Sep; 25(33):4904-4920. PubMed ID: 31543682
[TBL] [Abstract][Full Text] [Related]
10. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
[TBL] [Abstract][Full Text] [Related]
11. A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
Li X; Lu Y; Liang X; Zhou X; Li D; Zhang Z; Niu Y; Liu S; Ye L; Zhang R
PLoS One; 2023; 18(5):e0286257. PubMed ID: 37228085
[TBL] [Abstract][Full Text] [Related]
12. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
Hymel E; Vlock E; Fisher KW; Farazi PA
PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
[TBL] [Abstract][Full Text] [Related]
13. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
14. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
15. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
[TBL] [Abstract][Full Text] [Related]
16. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
19. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
